Medicines and Healthcare products Regulatory Agency chief executive Lawrence Tallon said on 2 July 2026 that the UK must adapt its regulatory approach to keep pace with advances in personalised medicine, artificial intelligence and cell and gene therapies. He highlighted the rapid progress in treating obesity, diabetes, cancer and rare diseases, and noted the MHRA’s new rare‑disease framework that replaces the traditional three‑phase trial system with an iterative Investigational Marketing Authorisation to shorten development timelines. Tallon also described the agency’s National Commission on AI in healthcare, which will publish a report in September that he expects to recommend fundamental regulatory changes. He urged that safety remain non‑negotiable while avoiding paternalism, and called for systems that are faster, more expert and open to innovation to keep the UK competitive in life‑sciences.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.